Literature DB >> 10409203

Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog.

L C Becker1, R W Jeremy, J Schaper, W Schaper.   

Abstract

To determine whether myocardial necrosis may occur during postischemic reperfusion, electron microscopy was used to identify morphological features of irreversible injury in myocardial samples taken from anesthetized dogs with 90-min ischemia and 0-, 5-, 90-, or 180-min reperfusion. In samples without detectable collateral blood flow, necrosis was almost complete, whether or not the myocardium was reperfused. In samples with collateral flow, necrosis was more frequent after 180-min reperfusion than in the absence of reperfusion, despite similar collateral flows in the two groups. Excess of necrosis after 180-min reperfusion was evident in endocardium (ischemia only: 4 of 13, 180-min reflow: 14 of 20; P = 0. 03) and midwall (ischemia only: 9 of 25, 180-min reflow: 29 of 45; P = 0.02). Multiple logistic regression with variables of collateral flow and transmural position was used to determine risk of irreversible injury in 111 samples from ischemic myocardium without reperfusion (model predictive accuracy = 75%, P < 0.00001) and to predict risk of necrosis in myocardium reperfused for 180 min. Of 65 samples from endocardium and midwall with detectable collateral flow, the model predicted necrosis in 23 samples but necrosis was observed in 43 samples (P < 0.01). Reperfusion duration was a determinant of frequency of irreversible injury. Multiple logistic regression for 186 samples from myocardium reperfused for 5, 90, or 180 min showed that reperfusion duration was an independent predictor of irreversible injury (P = 0.0003) when collateral flow and transmural location were accounted for. These findings are consistent with the occurrence of necrosis during reperfusion in myocardium exposed to substantial, prolonged ischemia but with sufficient residual perfusion to avoid necrosis during the period of flow impairment.

Entities:  

Mesh:

Year:  1999        PMID: 10409203     DOI: 10.1152/ajpheart.1999.277.1.H243

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Apoptosis and oncosis in acute coronary syndromes: assessment and implications.

Authors:  Bodh I Jugdutt; Halliday A Idikio
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

Review 2.  Nitric oxide and cardioprotection during ischemia-reperfusion.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

3.  AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.

Authors:  Bodh I Jugdutt; Vijayan Menon
Journal:  Mol Cell Biochem       Date:  2004-05       Impact factor: 3.396

4.  Apoptosis after reperfused myocardial infarction: Role of angiotensin II.

Authors:  Bodh I Jugdutt
Journal:  Exp Clin Cardiol       Date:  2004

5.  Nanoscale three-dimensional imaging of the human myocyte.

Authors:  Matthew S Sulkin; Fei Yang; Katherine M Holzem; Brandon Van Leer; Cliff Bugge; Jacob I Laughner; Karen Green; Igor R Efimov
Journal:  J Struct Biol       Date:  2014-08-23       Impact factor: 2.867

Review 6.  Nitric oxide and cardiovascular protection.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

7.  Insights into the interstitium of ventricular myocardium: interstitial Cajal-like cells (ICLC).

Authors:  L M Popescu; Mihaela Gherghiceanu; M E Hinescu; D Cretoiu; Laura Ceafalan; T Regalia; A C Popescu; Carmen Ardeleanu; E Mandache
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

8.  Intermittent Short-Duration Re-oxygenation Attenuates Cardiac Changes in Response to Hypoxia: Histological, Ultrastructural and Oxidant/Antioxidant Parameters.

Authors:  Ayed A Shati; Mohamed Samir A Zaki; Youssef A Alqahtani; Mohamed A Haidara; Mohammed A Alshehri; Amal F Dawood; Refaat A Eid
Journal:  Br J Biomed Sci       Date:  2022-03-18       Impact factor: 2.432

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.